# Artificial Muscle

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artificial-muscle

- Industry: Healthcare IT
- Headquarters: Sunnyvale, US
- Website: www.artificialmuscle.com
- Total disclosed funding: $24M
- Latest round: Series B (Apr 4, 2007)
- Investors on record: 8

## About

Artificial Muscle develops advanced materials that replicate human muscle functionality, focusing on innovative actuators for applications in robotics, prosthetics, and consumer electronics.Artificial Muscle, founded in 2003 in Sunnyvale, US, specializes in creating artificial muscles and soft robotics components. In March 2010, Bayer MaterialScience acquired the company after securing funding through a SERIES B round led by AllianceBernstein, raising USD 20.230 mn and achieving a current valuation of USD 51.933 mn. The company has completed a total of 3 deals since its inception.Artificial Muscle specializes in advanced materials designed to mimic the functionality of human muscle, primarily through its innovative actuators. The company's flagship products include artificial muscles and soft robotics components, employed in various applications from robotics and prosthetics to consumer electronics. These products are engineered to provide lightweight, efficient, and adaptable solutions that enhance the capabilities of machines and devices in sensitive environments. The technology addresses pressing needs in industries such as healthcare, where prosthetic limbs require natural movement, and robotics, which increasingly demand more dexterous and responsive components. Artificial Muscle markets its products globally, focusing on North America, Europe, and parts of Asia, where demand for high-performance robotics and medical devices is growing rapidly.Artificial Muscle generates revenue through a combination of direct sales and strategic partnerships across various sectors. The company engages in B2B transactions, supplying its advanced materials to manufacturers of robotic systems and medical devices. Transactions are structured around bulk orders with clients who integrate these artificial muscles into their products, enhancing functionality and market appeal. Pricing plans are tailored to specific applications and order volumes, aligning with the unique needs of each customer segment. Revenue streams are bolstered by collaborative projects with research institutions and businesses innovating within the robotics and healthcare industries.Looking ahead, Artificial Muscle plans to launch new products focused on enhancing the performance of their artificial muscle technology. The company aims to expand into new markets, targeting regions in Asia and Europe by 2012. The recent funding from the SERIES B round will be utilized to support product development and market expansion initiatives.

## Funding rounds

- Series B, Apr 4, 2007, $20M — ARCH Venture Partners, NGEN Partners, Vanguard Ventures, Chevron Technology Ventures, Parker Hannifin Corp, Micron Technology, Inc., AllianceBernstein
- Series A, Feb 28, 2004, $3.3M — ARCH Venture Partners, NGEN Partners, Vanguard Ventures, SRI International

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- NGEN Partners (https://capitalatlas.ai/funds/ngen-partners) — Series A, Series B
- Vanguard Ventures (https://capitalatlas.ai/funds/vanguard-ventures) — Series A, Series B
- SRI International — Series A
- Chevron Technology Ventures (https://capitalatlas.ai/funds/chevron-technology-ventures) — Series B
- Parker Hannifin Corp — Series B
- Micron Technology, Inc. — Series B
- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series B